Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Spruce Biosciences (SPRB) Debt to Equity (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Debt to Equity for 4 consecutive years, with $0.1 as the latest value for Q3 2025.

  • Quarterly Debt to Equity rose 140.8% to $0.1 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $0.1 through Sep 2025, up 140.8% year-over-year, with the annual reading at $0.06 for FY2024, 38.81% up from the prior year.
  • Debt to Equity for Q3 2025 was $0.1 at Spruce Biosciences, up from $0.07 in the prior quarter.
  • The five-year high for Debt to Equity was $0.1 in Q3 2025, with the low at $0.04 in Q3 2024.
  • Average Debt to Equity over 4 years is $0.06, with a median of $0.05 recorded in 2022.
  • The sharpest move saw Debt to Equity crashed 39.19% in 2023, then soared 140.8% in 2025.
  • Over 4 years, Debt to Equity stood at $0.07 in 2022, then plummeted by 39.19% to $0.04 in 2023, then skyrocketed by 38.81% to $0.06 in 2024, then soared by 65.19% to $0.1 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.1, $0.07, and $0.09 for Q3 2025, Q2 2025, and Q1 2025 respectively.